No Data
Top Gap Ups and Downs on Monday: SAP, TM, MUFG and More
Asian Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
Nomura Holdings Full-Year Profit Surges 105%
The Nikkei average is up 134 yen, rising for the fourth consecutive day, but the outlook is heavy on the upside = afternoon session on the 28th.
On the 28th, the Nikkei average stock price in the afternoon session rose by 134 yen and 25 sen compared to the previous weekend, reaching 35,839 yen and 99 sen, marking the fourth consecutive increase. The TOPIX (Tokyo Stock Price Index) also increased by 22.58 points to 2,650.61 points. At 9:34 AM, the Nikkei average hit 36,075 yen and 26 sen with an increase of 369 yen and 52 sen, briefly recovering to the 36,000 yen level for the first time in about a month during trading hours. However, lacking in clues, profit-taking selling capped the upward movement.
April 28th [Today's Investment Strategy]
[Fisco Selected Stocks]【Material Stocks】Hokkan Holdings <5902> 1,699 yen (4/25) Engaged in food cans, PET bottles, and filling business. The profit forecast for the fiscal year ending March 2025 has been revised upward. The estimated operating profit is 4.5 billion yen (up 2.5% from the previous year). This is an upward revision of about 9% from the previous financial estimates, resulting in a projected increase in profit. Revenue is expected to be lower than the previous forecast, but due to cost reductions in factory expenses and Logistics costs, profit has been upwardly revised. The year-end Dividends have been set at 70 yen.
Astellas Pharma and Hokkan Holdings are in the spotlight, while Nitto Denko and Yamazaki Baking seem to be underperforming.
Last weekend on the 25th, in the US Stocks market, the Dow Jones Industrial Average rose by 20.10 points to 40,113.50, the Nasdaq Composite Index increased by 216.90 points to 17,382.94, and the Chicago Nikkei 225 Futures were up by 220 yen compared to the Osaka daytime at 36,000 yen. The exchange rate was 1 dollar = 143.70-80 yen. In today's Tokyo market, Astellas Pharma <4503>, which experienced a significant increase in operating profit for the fiscal year ending March 2025, at 60.8% growth from a previous financial estimate of a 56.9% decline.
